Indianapolis Business Journal

MARCH 28-APRIL 3, 2016

Eli Lilly and Co. is making a play for a market expected to grow to $80 billion by 2020. But to make a dent with its new drug for arthritis, the pharmaceutical giant must prove it’s better than the proven medicines already prescribed, John Russell reports. Also in this week’s issue, Anthony Schoettle takes stock of Visit Indy’s strategy to sink all of its marketing funds for city tourism into digital content. And in A&E Etc., Lou Harry explores the blockbuster exhibit dedicated to 200 years of Indiana art.

Front PageBack to Top

Top StoriesBack to Top

FocusBack to Top

OpinionBack to Top

In BriefBack to Top